



September 10, 2014

Galectin Therapeutics to Present at Aegis Capital Corporation 2014 Healthcare and Technology Conference

NORCROSS, Ga., Sept. 10, 2014 (GLOBE NEWSWIRE) -- **Galectin Therapeutics Inc.** (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the Company will present at the Aegis Capital Corporation 2014 Healthcare and Technology Conference in Las Vegas, Nev., on Friday, September 12, 2014 at 1 p.m. Pacific Daylight Time. Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics, will provide a corporate update and an overview of development programs, including the Company's ongoing Phase 1 clinical trial of its proprietary galectin inhibitor in fatty liver disease (NASH).

The presentation will be available via webcast at <http://wsw.com/webcast/aegis/galt>. An archived version will be posted on the Galectin Therapeutics website, www.galectintherapeutics.com, following the presentation.

WHAT: Galectin Therapeutics presentation at Aegis Capital Corporation 2014 Healthcare and Technology Conference

WHO: Presentation by Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics

WHEN: Friday, September 12, 2014, 1:00 p.m. PDT

WHERE: The Encore and Wynn Las Vegas, Las Vegas, Nev.

The Aegis Capital Corporation Healthcare and Technology Conference is a forum to introduce small-cap companies in the life sciences and technology sectors to the investment community. The conference attracts a wide array of research analysts, fund managers, qualified high net worth individuals and financial advisors seeking compelling ideas for their portfolios. The conference is hosted by Aegis Capital, a leader in providing capital raising and financial advisory services for emerging growth companies.

"The Aegis conference provides another solid opportunity to educate a significant number of investors on the strength of our core business strategy and, as a result of progress in our Phase 1 clinical trial, on the growing opportunity for the Company within the emerging NASH market," said Dr. Traber.

For more information on the Aegis conference, visit <http://www.aegiscapcorp.com/>.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that our development program for GR-MD-02 will lead to the first therapy for the treatment of fatty liver disease with fibrosis. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that we may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of our other drugs in development. Our current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Regardless of

the results of any of our development programs, we may be unsuccessful in developing partnerships with other companies that would allow us to further develop and/or fund any studies or trials. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

CONTACT: Galectin Therapeutics Inc.

Peter G. Traber, MD, 678-620-3186

President, CEO, & CMO

ir@gallectintherapeutics.com